Elysium and the quest to bottle the fountain of youth

This post was originally published on this site

Curated by: Startups

 

Alice Lloyd George Contributor Share on Twitter Alice Lloyd George is an early stage investor based in New York and the host of Flux, a series of podcast conversations with leaders in frontier technology. More posts by this contributor One billion 3D views and counting Thomas Reardon and CTRL-Labs are building an API for the brain

In the latest episode of Flux podcast, I sit down with Eric Marcotulli, the co-founder of Elysium, a life sciences company developing consumer-facing health products based on aging research. The company’s first product is Basis, a supplement that combines compounds designed to increase NAD levels and activate sirtuins, boosting cellular health and longevity.

In this conversation we discuss why precursor companies failed, including Cambridge-based Sirtris Pharmaceuticals, which was bought for $720 million in 2008. Eric explains how Elysium is a platform-based company that will sell a host of products and diagnostics, why he believes direct to consumer is the best market strategy, and what the current user base looks like. The company just announced a new clinical trial this week. Eric gets into the importance of bringing academic rigor and peer review

contactedorg

%d bloggers like this: